Merck's experimental pill enlicitide sharply lowered cholesterol in a large study - Takeaways - MDSpire

Merck's investigational medication enlicitide significantly decreased cholesterol levels in a large-scale study

Share

1

Merck's investigational medication enlicitide significantly reduced LDL cholesterol by up to 60% in high-risk patients over six months.
2

Enlicitide offers a potential oral alternative to injected medications for cholesterol reduction in patients not adequately managed by statins.
3

The study involved over 2,900 participants and showed no safety differences between enlicitide and placebo.
4

FDA approval for enlicitide is being sought, with the drug included in a program for expedited reviews.
5

Further research is needed to determine if enlicitide's cholesterol reduction leads to fewer heart attacks and strokes.